Chemomab Therapeutics Ltd. (CMMB)
| Market Cap | 323.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.61M |
| Shares Out | 10.70M |
| EPS (ttm) | -24.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 21 |
| Last Price | $30.23 |
| Previous Close | $30.39 |
| Change ($) | -0.16 |
| Change (%) | -0.53% |
| Day's Open | 30.91 |
| Day's Range | 28.28 - 32.50 |
| Day's Volume | 145,974 |
| 52-Week Range | 25.33 - 2,700.80 |
TEL-AVIV, Israel, March 29, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibr...
Anchiano s hareholders approve all resolutions at shareholder meeting
Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.
Anchiano Therapeutics (ANCN) stock is rocketing higher on Monday after a shareholder letter caught the interest of investors. The post ANCN Stock: Speculation Around Investor Letter Sends Anchiano Thera...
ANCN stock is an early stage company engaged in clinical trials for rare liver, lung and skin diseases with no FDA-approved options now. The post ANCN Stock: 10 Things to Know as Anchiano Therapeutics R...
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or ...
NEW YORK, Dec. 24, 2020 /PRNewswire/ -- Anchiano Therapeutics Ltd. (NASDAQ: ANCN) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger o...
NEW YORK, Dec. 15, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Anchiano Therapeutics Ltd. ("Anchiano" ...
Anchiano Therapeutics (ANCN) stock is soaring higher on Tuesday following news of a merger with Chemomab that will bring major changes. The post ANCN Stock: Why Anchiano Therapeutics Stock Is Blasting H...
As of Dec. 10, the GuruFocus All-in-One Screener, a Premium feature, found that the following health care companies have low price-earnings ratios and are owned by gurus. While some of them are great va...
Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPa...
CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s 202...
About CMMB
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
| Industry Biotechnology | Founded 2004 |
| Stock Exchange NASDAQ | Ticker Symbol CMMB |